List view / Grid view




Bristol-Myers Squibb and Calibr sign worldwide agreement focused on new treatment approaches for fibrotic diseases

5 January 2015 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and the California Institute for Biomedical Research (Calibr) announced they have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration...